TYMS and colorectal carcinoma: First‐line chemotherapy of CRC uses 5‐FU, a pyrimidine analogue that inhibits thymidylate synthase, and whose metabolic activation results in its incorporation into RNA, which interferes with RNA function and prevents DNA synthesis.